Magnitude of ST-segment Elevation Is Associated with Increased Acute Inflammatory Response and Myocardial Scar in Patients with Acute Myocardial Infarction Undergoing pPCI

1. Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41:12-85. doi: 10.1093/eurheartj/ehz859.10.1093/eurheartj/ehz85931820000Search in Google Scholar

2. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165. doi: 10.1093/eurheartj/ehy394.10.1093/eurheartj/ehy39430165437Search in Google Scholar

3. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction. J Am Coll Cardiol. 2018;72:2231-2264. doi: 10.1016/j.jacc.2018.08.1038.10.1016/j.jacc.2018.08.103830153967Search in Google Scholar

4. Balci B. Tombstoning ST-Elevation Myocardial Infarction. Curr Cardiol Rev. 2009;5:273-278. doi:10.2174/157340309789317869.10.2174/157340309789317869284295921037844Search in Google Scholar

5. Wong DT, Leung MC, Das R, et al. Intracoronary ECG ST-segment recovery during primary percutaneous intervention for ST-segment myocardial infarction: insights from a cardiac MRI study. Catheter Cardiovasc Interv. 2012;80:746-53. doi: 10.1002/ccd.23455.10.1002/ccd.2345522422674Search in Google Scholar

6. Opincariu D, Chițu M, Rat N, Benedek I. Integrated ST segment elevation scores and in-hospital mortality in STEMI patients undergoing primary PCI. Journal of Cardiovascular Emergencies. 2016;2:114-121. doi: 10.1515/jce-2016-0018.10.1515/jce-2016-0018Search in Google Scholar

7. Ahmed N, Carberry J, Teng V, Carrick D, Berry C. Risk assessment in patients with an acute ST-elevation myocardial infarction. J Comp Eff Res. 2016;5:581-593. doi: 10.2217/cer-2016-0017.10.2217/cer-2016-0017598550027580675Search in Google Scholar

8. Oh PC, Eom YS, Moon J, et al. Addition of routine blood biomarkers to TIMI risk score improves predictive performance of 1-year mortality in patients with ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2020;20:486. doi: 10.1186/s12872-020-01777-7.10.1186/s12872-020-01777-7767298033208092Search in Google Scholar

9. Ortolani P, Marzocchi A, Marrozzini C, et al. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J. 2008;29:1241-1249. doi: 10.1093/eurheartj/ehm338.10.1093/eurheartj/ehm33817766280Search in Google Scholar

10. Cağli KE, Topaloğlu S, Aras D, et al. Akut miyokard infarktüsü nedeniyle primer perkütan girişim uygulanan hastalarda başvuru anindaki hs-CRP düzeyinin önemi [The significance of admission hs-CRP in patients undergoing primary percutaneous intervention for acute myocardial infarction]. Turk Kardiyol Dern Ars. 2009;37:19-25.Search in Google Scholar

11. Al Aseri ZA, Habib SS, Marzouk A. Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction. Vasc Health Risk Manag. 2019;15:221-227. doi: 10.2147/VHRM.S198452.10.2147/VHRM.S198452664325831410012Search in Google Scholar

12. Zhao X, Liu C, Zhou P, et al. Estimation of Major Adverse Cardiovascular Events in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Risk Prediction Score Model From a Derivation and Validation Study. Front Cardiovasc Med. 2020;7:603621. doi: 10.3389/fcvm.2020.603621.10.3389/fcvm.2020.603621772866933330667Search in Google Scholar

13. Fanola CL, Morrow DA, Cannon CP, et al. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017;6:e005637. doi: 10.1161/JAHA.117.005637.10.1161/JAHA.117.005637572182529066436Search in Google Scholar

14. Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020;41:2952-2961. doi: 10.1093/eurheartj/ehaa160.10.1093/eurheartj/ehaa160745383332221587Search in Google Scholar

15. Salerno M, Sharif B, Arheden H, et al. Recent Advances in Cardiovascular Magnetic Resonance: Techniques and Applications. Circ Cardiovasc Imaging. 2017;10:e003951. doi:10.1161/CIRCIMAGING.116.003951.10.1161/CIRCIMAGING.116.003951577785928611116Search in Google Scholar

16. Larose E, Rodés-Cabau J, Pibarot P, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol. 2010;55:2459-2469. doi: 10.1016/j.jacc.2010.02.033.10.1016/j.jacc.2010.02.03320510213Search in Google Scholar

17. Eitel I, Stiermaier T, Lange T, et al. Cardiac Magnetic Resonance Myocardial Feature Tracking for Optimized Prediction of Cardiovascular Events Following Myocardial Infarction. JACC Cardiovasc Imaging. 2018;11:1433-1444. doi: 10.1016/j.jcmg.2017.11.034.10.1016/j.jcmg.2017.11.03429454776Search in Google Scholar

18. Morariu M, Márton E, Mester A, Rațiu M, Benedek I. Association Between Acute Inflammatory Response and Infarct Size in Stemi Patients Undergoing Primary PCI. Journal Of Cardiovascular Emergencies. 2018;4:140-146. doi: 10.2478/jce-2018-0017.10.2478/jce-2018-0017Search in Google Scholar

19. Świątkiewicz I, Magielski P, Kubica J, Zadourian A, DeMaria AN, Taub PR. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. Int J Mol Sci. 2020;21:807. doi: 10.3390/ijms21030807.10.3390/ijms21030807703752131991903Search in Google Scholar

20. Chen RZ, Liu C, Zhou P, et al. [Associations between postprocedural D-dimer, hs-CRP, LDL-C levels and prognosis of acute myocardial infarction patients treated by percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:359-366. Chinese. doi: 10.3760/cma.j.cn112148-20190829-00527.Search in Google Scholar

21. Kim D, Choi DH, Kim BB, Choi SW, Park KH, Song H. Prediction of Infarct Transmurality From C-Reactive Protein Level and Mean Platelet Volume in Patients With ST-Elevation Myocardial Infarction: Comparison of the Predictive Values of Cardiac Enzymes. J Clin Lab Anal. 2016;30:930-940. doi: 10.1002/jcla.21959.10.1002/jcla.21959680700527075615Search in Google Scholar

22. Stone GW, Selker HP, Thiele H, et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016;67:1674-1683. doi: 10.1016/j.jacc.2016.01.069.10.1016/j.jacc.2016.01.06927056772Search in Google Scholar

23. Reindl M, Eitel I, Reinstadler SJ. Role of Cardiac Magnetic Resonance to Improve Risk Prediction Following Acute ST-Elevation Myocardial Infarction. J Clin Med. 2020;9:1041. doi: 10.3390/jcm9041041.10.3390/jcm9041041723109532272692Search in Google Scholar

24. Reinstadler SJ, Thiele H, Eitel I. Risk stratification by cardiac magnetic resonance imaging after ST-elevation myocardial infarction. Curr Opin Cardiol. 2015;30:681-689. doi: 10.1097/HCO.0000000000000227.10.1097/HCO.000000000000022726398412Search in Google Scholar

25. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016;68:539-551. doi: 10.1016/j. ihj.2016.04.006.Search in Google Scholar